Alk, A Trimble Company company information, Employees & Contact Information

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 PR Newswire

ALK in cancer: from function to therapeutic targeting Nature

ARS Pharmaceuticals Partners with ALK for Neffy Promotion Investing.com

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer | Cell Death & Disease Nature

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire

ARS Pharmaceuticals Announces Exclusive Agreement with GlobeNewswire

ALK Stock Quote Price and Forecast CNN

Welcome to investor relations Alaska Airlines

Neladalkib Showcases Early Activity in ALK+ Solid Tumors OncLive

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells ScienceDirect.com

Alaska Air Group (ALK): Assessing Valuation as Iceland Route Expands Transatlantic Reach and International Strategy Yahoo Finance

HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy | Leukemia Nature

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance Nature

Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma Nature

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC Nature

ALK peptide vaccination restores the immunogenicity of ALK -rearranged non-small cell lung cancer Nature

ALK fusions in the pan-cancer setting: another tumor-agnostic target? Nature

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors Nature

Gilteritinib overcomes lorlatinib resistance in ALK -rearranged cancer Nature

Novel TENM3–ALK fusion is an alternate mechanism for ALK activation in neuroblastoma Nature

Structural basis of cytokine-mediated activation of ALK family receptors Nature

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features Nature

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma Nature

Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms | Modern Pathology Nature

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer Nature

Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings Nature

Alaska Air Group (ALK) Advances While Market Declines: Some Information for Investors Yahoo Finance

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement Nature

ALK Announces New AllerTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis PR Newswire

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents PR Newswire

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC CancerNetwork

A retrospective study of postoperative targeted therapy in ALK-positive lung cancer | Scientific Reports Nature

Alaska Air Group, Inc. (ALK) Reports Q2 2025 Results; Earnings Beat Expectations Yahoo Finance

ALK variants, PD-L1 expression, and their association with outcomes in ALK -positive NSCLC patients Nature

ALK Summit 24 Agenda is out! – ALK Positive Oncodaily

The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer Journal of Experimental & Clinical Cancer Research

ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions Nature

Alkane Resources (ASX:ALK) Valuation in Focus After Joining Two Key S&P/ASX Indices Yahoo Finance

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 PR Newswire

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer Nature

The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status Nature

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial The Lancet

ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC Medscape

ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217 Nature

Burnley owners ALK Capital in talks over buying Espanyol stake The New York Times

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment Nature

A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma BMC Pulmonary Medicine

Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer Nature

EGFR and ALK Inhibitors in NSCLC Lead to Resistance Challenge OncLive

Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases Nature

Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors Nature

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) - Du - 2018 - Thoracic Cancer Wiley Online Library

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib) PR Newswire

Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC) Novartis

Lorlatinib found to be safe and effective for patients with ALK-driven relapsed/refractory high-risk neuroblastoma Medical Xpress

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial The Lancet

Alaska Air Group (ALK) Stock Price, News & Analysis MarketBeat

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer Nature

Alaska Air Group (ALK): Company Profile, Stock Price, News, Rankings Fortune

Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy Abbott MediaRoom

ALK Technologies Sold To Trimble communitynews.org

Alaska Air Group (ALK) Zacks Investment Research